Tag: licensing
-
Biogen Idec, Isis Pharma Partner on Muscular Dystrophy Drug
The biotechnology companies Biogen Idec in Weston, Massachusetts and Isis Pharmaceuticals in Carlsbad, California have agreed to develop and commercialize an antisense treatment for myotonic dystrophy type 1, also known as Steinert disease. The deal, which involves Biogen Idec licensing antisense technology developed by Isis Pharmaceuticals, will gain Isis $12 million immediately and up to…
-
Lab Seeking Commercial Partners for Detection Technology
Sandia National Laboratory in Livermore, California is developing a new process that the lab says can make radiation detection in cargo and baggage more effective and less costly. Sandia lab is seeking partners to commercialize the new technology. The process, known as spectral shape discrimination, makes use of a new type of nanomaterials called metal-organic…
-
Robot Recommends and Plays Music Based on Listener Feedback
A robotic device developed at Georgia Institute of Technology, and licensed to a start-up company in Atlanta, can recommend songs based on listeners’ tastes, and even dance to the music selected. Shimi, a musical companion derived from technology developed at Georgia Tech’s Center for Music Technology, is expected to be demonstrated today at Google’s I/O…
-
Report: Foreign Scientists Key to U.S. Innovation, Patents
A new report on the impact of immigration on innovation in the U.S. says researchers from overseas account for a large majority of the patents granted to inventors from top research universities, particularly in high-growth science and engineering fields. The report, “Patent Pending: How Immigrants Are Reinventing The American Economy,” was prepared by the Partnership…
-
Selenium Found to Control Staph Bacteria on Implant Material
Engineers at Brown University in Rhode Island discovered the ability of selenium nanoparticles to control the growth of staph bacteria on a type of plastic often used in medical implants. Doctoral student Qi Wang and biomedical engineering professor Thomas Webster describe their research online this week in the Journal of Biomedical Materials Research A (paid…
-
GSK Licenses Nanotech Product Development Platform
The global pharmaceutical company GlaxoSmithKline (GSK) will license a nanotechnology-based product development platform created by Liquidia Technologies in North Carolina. The precise financial scale of the deal was not disclosed, but the companies say total earnings by Liquidia could reach as high as several hundred million dollars. Liquidia has built a development technology for pharmaceuticals…
-
Roche, Seaside Therapeutics to Partner on Autism, Fragile X
Seaside Therapeutics in Cambridge, Massachusetts and the Swiss pharmaceutical company Roche will collaborate to develop treatments for autism spectrum disorders and fragile X syndrome. Financial terms of the agreement were not disclosed. Autism spectrum disorders and fragile X syndrome are neurodevelopmental disorders for which there are no effective treatments yet that address core symptoms. Autism…
-
Merck, Ambrx to Partner on Biologics Candidate Development
Ambrx Inc., a biopharmaceutical company in La Jolla, California, will collaborate with the global pharmaceutical maker Merck, to design and develop biologic drug conjugates, antibodies connected to drug payloads that bind with disease cell targets. The deal has a value of up to $303 million for Ambrx. The agreement gives Merck worldwide rights to develop…
-
Patent Awarded for Curry Compound as Drug Ingredient
A patent has been awarded for compounds based on a substance in the spices curry and turmeric, to use in treatments for a number of diseases, including some cancers. Patent number 8,198,323 was awarded yesterday by the U.S. Patent and Trademark Office to nine inventors, and assigned to University of Rochester in New York, University…
-
Patent Awarded for Sustained Release Drug Implant in Eyes
The company pSivida Corp., a medical device developer in Watertown, Massachusetts, has received a patent for its system to continuously deliver drugs to the eyes. The U.S. Patent and Trademark Office awarded patent number 8,192,408 yesterday (5 June) to four inventors, including pSivida vice-presidents Martin Nazzaro and Hong Guo, and assigned it to pSivida. The…